Amyloid-beta plaque growth in cognitively normal adults: Longitudinal [ 11C]Pittsburgh compound B data

Annals of Neurology

Volumn 70, Issue 5, 2011, Pages 857-861

  Vlassenko, Andrei G ^a,b   Mintun, Mark A ^a,c   Xiong, Chengjie ^b   Sheline, Yvette I ^a,b   Goate, Alison M ^b   Benzinger, Tammie L S ^a,b   Morris, John C ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON4; PITTSBURGH COMPOUND B; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANTERIOR CINGULATE; ARTICLE; CAUDATE NUCLEUS; FEMALE; HUMAN; INCIDENCE; MALE; NORMAL HUMAN; OCCIPITAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; BENZOTHIAZOLES; BRAIN; CARBON RADIOISOTOPES; COGNITION; EARLY DIAGNOSIS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY;

EID: 83255181779     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22608     Document Type: Article

References (18)

1. Hardy J, Selkoe DJ,. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
2. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-223.
3. Price JL, Ko AI, Wade MJ, et al. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 2001; 58: 1395-1402.
4. Price JL, Morris JC,. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999; 45: 358-368.
5. Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009; 66: 1469-1475.
6. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129: 2856-2866.
7. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132: 1355-1365.
8. Scheinin NM, Aalto S, Koikkalainen J, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 2009; 73: 1186-1192.
9. Grimmer T, Tholen S, Yousefi BH, et al. Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimer's disease. Biol Psychiatry 2010; 68: 879-884.
10. Sojkova J, Zhou Y, An Y, et al. Longitudinal patterns of β-amyloid deposition in nondemented older adults. Arch Neurol 2011; 68: 644-649.
11. Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011; 69: 181-192.
12. Morris JC,. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414.
13. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-452.
14. Milliken GA, Johnson DE,. Analysis of Covariance. In: Analysis of messy data. New York, NY: Chapman & Hall/CRC, 2001; pp 1-596.
15. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009; 106: 6820-6825.
16. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010; 67: 122-131.
17. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630-1645.
18. Cairns NJ, Ikonomovic MD, Benzinger T, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol 2009; 66: 1557-1562.